KalVista Pharmaceuticals, Inc

Pulmatrix, Inc., based in Framingham, MA, is at the forefront of developing innovative pulmonary therapeutics utilizing their proprietary iSPERSE technology. The company is dedicated to transforming patient care and enhancing treatment options for individuals with serious diseases. With a mission to change medicine through advanced delivery systems, Pulmatrix is pioneering new horizons in the field of pulmonary health. Their commitment to innovation positions them as a leader in the development of next-generation therapies. Generated from the website

Blue Oak Pharmaceuticals Inc is a pioneering biopharmaceutical company based in Concord, MA, dedicated to revolutionizing the treatment of brain disorders. With a focus on developing first-in-class and best-in-class drugs, their breakthrough approach challenges the traditional target-based methods used by the industry, offering new hope to millions of patients and their families who suffer from mental illness. By utilizing an unbiased approach to systems neuroscience and leveraging their privileged chemistry platform, Blue Oak is able to examine the entire brain circuitry and identify drug-like compounds with high efficiency. Their innovative use of predictive AI design, in collaboration with partners Exscientia and PsychoGenics, optimizes small molecules to normalize the behavioral symptoms of brain disorders. With a robust pipeline of clinical programs targeting bipolar depression, treatment-resistant depression, schizophrenia, and geriatric psychosis, Blue Oak is at the forefront of transforming the CNS drug discovery paradigm.Generated from the website

Syntonix Pharmaceuticals is engaged in the discovery and development of novel, long-acting, proprietary therapeutic products that utilize the company s proprietary Fc-fusion proteins and other engineered ligands that bind to specific Fc receptors. These technologies, including the Transceptor drug-delivery platform, are designed to use the body s natural protection of antibodies against premature destruction and for the transport of antibodies across cell barriers. The company focuses on using these technologies to create next-generation treatments for chronic diseases such as hemophilia, anemia and autoimmune disorders. It develops selected products for specialty indications and evaluates and commercializes other products through partnerships. The company occupies a 25,000-square-foot laboratory facility that includes a clinical manufacturing suite. Syntonix Pharmaceuticals is headquartered in Waltham, Mass.